The UK's largest event for private investors

Business Design Centre, London, 29 March 2025








Juvenescence logo

Juvenescence Therapeutics

Juvenescence Therapeutics (JuvRx) is the division within Juvenescence dedicated to developing novel medicines to treat age-related diseases, comprising our majority and wholly owned first-in-class medicines.

Our mission is to prolong the period of life spent in health (healthspan) with novel therapeutics that target the underlying causes of age-related disease. Our work is based on the novel scientific understanding of the underlying biological causes of ageing. We aim to get life-changing therapeutics to patients and enable people to improve their health in a preventative fashion. JuvRx is being led by an experienced technical team of drug developers who, combined, have made major contributions to drug peak sales of more than $30 billion, led by Richard Marshall who was awarded a CBE whilst at Astra Zeneca for his work on the covid vaccine.

We have a pipeline of therapies entering human studies in the next 12 months, including:

  • First-in-class oral PAI-1 inhibitor for fibrotic lung/kidney disease – IND filing imminent with Phase 1 starting in Q1 2024
  • GDF15 mAb on the path to a Phase 1 in Q3 2024 and follow on bispecific mAb (with Activin A) entering preclinical development
  • First-in-class oral CD38 inhibitor for Rheumatoid Arthritis – on track for Phase 1 commencement in Q4 2024

Get your ticket

Don't miss out on the UK's largest event for private investors - secure your ticket today.